Evidence map›Paper›PMID 31308388›Full record

ArticleScientific reports2019

HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers.

Tinashe E Nyanhete, Alyse L Frisbee, Todd Bradley, William J Faison, Elizabeth Robins, Tamika Payne, Stephanie A Freel, Sheetal Sawant, Kent J Weinhold, Kevin Wiehe and 5 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Tinashe E NyanheteDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.ORCID http://orcid.org/0000-0002-4924-3746
Alyse L FrisbeeDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Todd BradleyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
William J FaisonDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Elizabeth RobinsDepartment of Immunology, Duke University School of Medicine, Durham, NC, 27710, USA.
Tamika PayneDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Stephanie A FreelDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Sheetal SawantDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Kent J WeinholdDepartment of Immunology, Duke University School of Medicine, Durham, NC, 27710, USA.
Kevin WieheDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Guido FerrariDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Qi-Jing LiDepartment of Immunology, Duke University School of Medicine, Durham, NC, 27710, USA.
M Anthony MoodyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Georgia D TomarasDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA. gdt@duke.edu.
Duke University · US

Funding

Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2012 to 2018
$204.7M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
Basic Immunology Training ProgramT32AI052077 · NIAID · DUKE UNIVERSITY · PI KRANGEL, MICHAEL S · 2002 to 2024
$4.2M
HIV-1 Gene Suppression by CD8+ T CellsR01AI052779 · NIAID · DUKE UNIVERSITY · PI TOMARAS, GEORGIA DORIS · 2003 to 2010
$1.9M
Data commons for 'omic, microscopy and analysis core facilitiesS10OD018164 · OD · DUKE UNIVERSITY · PI WRAY, GREGORY A. · 2014 to 2014
$598k
HIV-1 Gene Suppression by CD8+ T CellsR56AI052779 · NIAID · DUKE UNIVERSITY · PI TOMARAS, GEORGIA DORIS · 2012 to 2012
$388k
Epigenetic Control of the CD8+ T-cell Response to HIVF31AI106519 · NIAID · DUKE UNIVERSITY · PI JOHN, TAMIKA L. · 2013 to 2014
$62k
NIAID NIH HHS F31 AI106519NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI052779NIAID NIH HHS R56 AI052779NIAID NIH HHS T32 AI052077NIAID NIH HHS UM1 AI100645NIH HHS S10 OD018164
6 · The paper itself

Abstract

A paradigm shifting study demonstrated that induction of MHC class E and II-restricted CD8+ T cells was associated with the clearance of SIV infection in rhesus macaques. Another recent study highlighted the presence of HIV-1-specific class II-restricted CD8+ T cells in HIV-1 patients who naturally control infection (virus controllers; VCs). However, questions regarding class II-restricted CD8+ T cells ontogeny, distribution across different HIV-1 disease states and their role in viral control remain unclear. In this study, we investigated the distribution and anti-viral properties of HLA-DRB1*0701 and DQB1*0501 class II-restricted CD8+ T cells in different HIV-1 patient cohorts; and whether class II-restricted CD8+ T cells represent a unique T cell subset. We show that memory class II-restricted CD8+ T cell responses were more often detectable in VCs than in chronically infected patients, but not in healthy seronegative donors. We also demonstrate that VC CD8+ T cells inhibit virus replication in both a class I- and class II-dependent manner, and that in two VC patients the class II-restricted CD8+ T cells with an anti-viral gene signature expressed both CD4+ and CD8+ T cell lineage-specific genes. These data demonstrated that anti-viral memory class II-restricted CD8+ T cells with hybrid CD4+ and CD8+ features are present during natural HIV-1 infection.

Indexed as

AdultCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleHistocompatibility Antigens Class IIHIV-1HIV InfectionsHIV SeropositivityHLA-DQ beta-ChainsHLA-DRB1 ChainsHumansMaleViral LoadVirus ReplicationHistocompatibility Antigens Class IIHLA-DQB1 antigenHLA-DQ beta-ChainsHLA-DRB1 Chains

Identifiers

PMID31308388
PMCPMC6629643
OpenAlexW2960061342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.